Oklahoma City will be site of the nonprofit alliance’s first major program roll out.
trial
Dr. Prescott: This is why we need clinical trials
Desperate times call for desperate measures.
An OMRF employee finds a new lease on life—at work
In MS, immune cells attack the protective covering of nerves in the brain, causing vision problems, tremors, paralysis, painful spasms, imbalance and cognitive changes.
OMRF seeks lupus family members for prevention study
OMRF scientists need volunteers for the world’s first lupus prevention study.
A name for his pain
David Key had never heard of sarcoidosis—until the rare disease stole his health.
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.